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Abstract : Purpose : Antiresorptive agents, such as bisphosphonates, are useful for the prevention of the recur-
rence of hip fractures. However, their administration has a risk of antiresorptive agent-related osteonecrosis of 
the jaw (ARONJ), and risk factors include poor oral hygiene. It is difficult for an orthopedic surgeon to examine 
a patient’s oral condition thoroughly. This study evaluated the relationship between risk factors for ARONJ 
and intraoral findings in hip fracture patients. Materials and Methods : We evaluated 79 patients (average age 
of 82.2 years) with hip fracture surgery who underwent an oral assessment by dentists. The risk assessments of 
the intraoral findings were classified into four levels (levels 0-3), with levels 2 and 3 requiring dental treatment 
intervention. Data that could be extracted as risk factors of ARONJ were also examined. Results : Level 1 was 
found most frequently (54.4%), followed by level 0 (35.4%), level 2 (8.9%), level 3 (1.3%). The area under the receiver 
operating characteristic curve for the number of risk factors for the two groups (dental treatment intervention 
required and unnecessary) and oral findings were 0.732. When the cut-off value was set to two risk factors, the 
specificity and sensitivity was 53.5% and 87.5%. Conclusions : For hip fracture patients with a more than 2 risk 
factors, dental visits are recommended to prevent ARONJ. This is a useful evaluation method that can be used to 
screen for ONJ from data obtained from other risk factors, even if it is difficult to evaluate the oral condition in 
hospitals where dentists are absent. J. Med. Invest. 67 : 328-331, August, 2020
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INTRODUCTION
 
Globally, the aging population has been increasing, and in 
Japan, the aging rate is particularly rapid. In the future, peo-
ple will live even longer, and it is estimated that 1 / 3 people in 
Japan will be over > 65 years old (1). Osteoporosis is one of the 
major disorders at risk of fractures and progresses with age. Hip 
fractures are a type of osteoporotic fracture and are frequently 
caused by low-energy trauma in osteoporotic patients (2). In 
addition to surgical treatment, it is crucial to administer an-
tiresorptive agents, such as bisphosphonates, in the treatment 
of osteoporotic hip fractures (3). This drug therapy is useful for 
preventing osteoporosis relapse and improving life prognosis 
during the perioperative period (3, 4). 
However, anti-receptor activator of nuclear factor κB ligand 
(RANKL) antibody preparations, which are classified as bone 
resorption inhibitors, and bisphosphonates have been shown to 
cause osteonecrosis of the jaw (ONJ) (5-7). Thus, the term antire-
sorptive agent-related ONJ (ARONJ) was adopted (8). Poor oral 
hygiene has been proposed by a position paper as a risk factor 
for ONJ (9). However, it is difficult for an orthopedic surgeon 
to determine the oral findings when initiating antiresorptive 
agent administration, and the oral findings require a dentist’s 
examination. Therefore, if the risk factors of ARONJ can be 
extracted from data other than a patient’s oral hygiene status, it 
is considered that proactively recommending dental visits after 
orthopedic surgery to patients with several risk factors, even in 
hospitals where dentists are absent, could be implemented.
Therefore, the purpose of the present study was to evaluate 
the intraoral findings in the perioperative period of hip fractures 
and extract the risk factors for ARONJ. 
MATERIALS AND METHODS
Patients
This retrospective study was performed at the Department 
of Orthopedic Surgery and Oral and Maxillofacial Surgery, 
Kagawa Prefectural Central Hospital, Kagawa, Japan, and was 
approved by the ethics committee of Kagawa Prefectural Central 
Hospital (Approval No. 863). The registries of patients between 
2018 and 2019 with hip fractures receiving surgical treatment, 
such as an open reduction and internal fixation or bipolar 
hemiarthroplasty (BHA), and whose oral status was evaluated 
during the perioperative period by a dentist at our hospital were 
retrospectively reviewed for possible inclusion in our study. All 
patients provided preoperative informed consent for undergoing 
surgical treatment of a hip fracture and for evaluating their oral 
condition during the perioperative period in the department of 
oral and maxillofacial surgery. All patients gave written con-
sent to the inclusion of material pertaining to themselves and 
acknowledged that they could not be identified via this paper. 
We ensured that they were all fully anonymized. The inclusion 
criteria were a hip fracture treated with surgery and sufficient 
medical records available for review indicating an adequate 
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medical condition and oral status. The exclusion criteria were a 
pathological hip fracture, patients who refused oral evaluation, 
and patients with insufficient medical information. The final 
study cohort consisted of 79 patients. 
Risk factors for ONJ
The risk factors for ONJ were classified as patient (obesi-
ty, smoking, the presence of malignant tumor, hemodialysis, 
anemia, and diabetes), dental (a history of dental surgery), or 
drug (steroids, the administration methods of bisphosphonate 
[injection or internal use], human anti-RANKL monoclonal anti-
body, and chemotherapy for cancer) factors. Obesity was defined 
as a body mass index ≥ 30 kg / m2, and anemia was defined as 
hemoglobin levels < 12 g / dL for women and < 13 g / dL for men, 
according to the World Health Organization guidelines (10). Di-
abetes was defined as ≥ 6.5% HbA1c, according to the National 
Glycohemoglobin Standardization Program (11). 
Outcome variables
The risk assessment results obtained from the oral findings 
were divided into two groups, which were clinically different in 
risk : level 0 and 1 (dental treatment unnecessary group) and 
level 2 and 3 (dental treatment necessary group). We analyzed 
the need for dentist intervention based on the number of risk 
factors and oral findings (Table 1).
Data sampling
All data from the previous clinical records were examined 
with respect to the necessity of dentist intervention as an out-
come variable and patient, dental, and drug factors as risk 
factors.
Statistical analysis
Data were recorded and entered using Microsoft Excel (Mic-
rosoft, Redmond, WA, USA) into an electronic database over the 
course of the study. The means and standard deviations were 
used when distribution was compatible with normality. Fisher’s 
exact method and Pearson’s chi-square test were used to analyze 
each group. An analysis of variance was conducted to compare 
the three groups. The database was transferred to JMP 11.2 
software for Macintosh computers (SAS Institute, Cary, NC, 
USA) for statistical analysis. A P-value of < 0.05 was considered 
statistically significant.
RESULTS
The average age of the 79 patients in the study cohort was 
82.2 years (range, 51-100 years), and included 61 women (77.2%) 
and 18 men (22.8%). The risk assessment for ONJ identified 
28 patients (35.4%) as level 0, 43 (54.4%) as level 1, 7 (8.9%) as 
level 2, and 1 (1.3%) as level 3. Most patients were level 1, and 
10.2% of the patients required dental intervention. Two patients 
among the level 2 patients were prescribed bisphosphonates 
without dental assessment before admission. One level 3 patient 
was newly administered bisphosphonate after admission before 
dental assessment. The risk factors included 60 patients with 
anemia (75.9%), 29 with malignant tumors (36.7%), and 11 with 
diabetes (13.9%). None of the patients were receiving intrave-
nous infusions of zoledronic acid.
There were 13 patients who had been treated for osteoporosis 
prior to hospitalization, of which four were using bisphospho-
nates. None of the patients were using RANKL inhibitors. There 
was no significant difference between the predictive factors 
of the dental treatment necessary group and the unnecessary 
group (Table 2).
The number of risk factors averaged 1.8 per patient, with an 
Table 1.　Risk classification based on intraoral findings for osteone-
crosis of the jaw.
Level Risk factors for osteonecrosis of the jaw considered from intraoral findings
0 Safe oral administration group, such as antiresorptive agents, with good oral hygiene and no oral lesions
1
Administrable group presenting local risk factors due to 
mild oral hygiene or non-infectious oral lesions, such as 
and mandibular protuberance
2
Careful administration group with local risk factors due 
to mild or poor oral hygiene and infectious lesions, such 
as mild periodontitis
3 Dosing avoidance group presenting risk factors due to poor oral hygiene and active infectious lesions due to pus









Age (years) 82.4 81.5 0.78
Sex (male / female) 16 / 55 2 / 6 0.87
Smoking (%) 15.4 12.5 0.82
Malignant tumor (%) 33.8 62.5 0.11
Hemodialysis (%) 4.2 25 0.22
Anemia (%) 73.2 100 0.09
Diabetes (%) 11.3 25 0.12
Obesity (%) 1.4 0 0.73
History of dental surgery (%) 1.4 12.5 0.19
Chemotherapy (%) 1.4 0 0.89
Taking steroids (%) 2.8 12.5 0.17
RANKL inhibitors (%) 5.6 0 0.64
Oral bisphosphonate (%) 26.8 12.5 0.34
Intravenous bisphosphonate (%) 8.5 37.5 0.14
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average of 2.5 for the dental intervention required group and 1.6 
for the unnecessary group. There were 10, 29, 21, 11, 5, 2, and 1 
patients with 0, 1, 2, 3, 4, 5, and 6 risk factors, respectively. The 
area under the receiver operating characteristic curve for the 
number of risk factors was 0.732 for the two groups (dental care 
intervention required and unnecessary) based on the oral risk 
assessment. When the cut-off value was set to two risk factors, 
the specificity was 53.5%, and the sensitivity was 87.5%, which 
was relatively high for screening (Table 3).
 
DISCUSSION
In this retrospective study, we observed that 10.2% of the pa-
tients with hip fracture required dental intervention for the risk 
assessment of ARONJ. Moreover, for patients with more than 2 
risk factors, dental visits are recommended to prevent ARONJ. 
In a clinical setting where hip fracture was treated, this is a 
useful and feasible evaluation method to screen for ARONJ with 
data obtained from the other risk factors except oral assessment.
Ideally, osteoporosis should be prevented before hip fractures 
occur, according to the International Society for Clinical Densi-
tometry (12). However, osteoporosis is typically asymptomatic 
until a fracture occurs and is considered an age-related chronic 
disease characterized by a loss of bone mass and quality. There-
fore, it is important to provide treatment for hip fracture patients 
to prevent subsequent fractures with increasing age. It is well 
known that the risk of subsequent hip fractures can be reduced 
by the initiation of osteoporosis treatment. It was reported that 
zoledronic acid significantly increased bone mineral density at 
the total hip by 5.5% (13). Furthermore, it significantly lowered 
the incidence of subsequent fractures at the hip by 33.8% (14). 
The use of antiresorptive agents for elderly hip fracture patients 
is highly beneficial. The patients with hip fractures in our study 
were elderly, with an average age of 82.2 years, and osteopo-
rosis was diagnosed according to the Japanese Guidelines for 
Prevention and Treatment of Osteoporosis (15). Therefore, our 
study cohort comprised patients who required drug treatment 
for osteoporosis.
ONJ is a complication that should be considered when admin-
istering antiresorptive agents. In 2003, Marx first reported a 
new clinical entity, ONJ, in oncology patients who had received 
high-dose intravenous bisphosphonates (15). ONJ was then 
described in patients with osteoporosis who were administered 
low-dose oral bisphosphonates (16). In addition to bisphospho-
nates, past reports have described that another type of antire-
sorptive medication, RANKL inhibitors, such as denosumab, 
might also be associated with an increased incidence of ONJ 
(17). Numerous investigators have reported ARONJ in both 
basic and clinical studies. Although the precise pathogenesis of 
ARONJ remains unelucidated, the presence of infectious oral 
lesions and poor oral condition have been reported as risk factors 
for the onset of ONJ (9, 18). The elderly population are prone to 
periodontitis and tend to experience a greater inflammatory 
insult to the alveolar bone (19, 20). It is essential to be able to 
safely initiate osteoporosis drug treatment by evaluating oral 
screening results. However, the oral cavity is complicated and 
includes lesions from the apex as well as periodontitis, and it is 
difficult for all orthopedic surgeons to perform an appropriate 
intraoral assessment in the same manner. Ideally, a dentist 
should be added to the Fracture Liaison Services team to further 
manage patient risk and prevent refracture. In reality, there are 
often no dentistry services available, so this would be difficult to 
achieve in all facilities. From this point of view, our examination 
of the relationship between oral risk factors and patient, dental, 
and drug factors is extremely significant and will aid in safe 
treatment in a hospital without dentists.
In the present study, the dental intervention group was con-
sidered to show an ONJ risk for the administration of antire-
sorptive agents. In previous reports, anemia and diabetes were 
considered as risk factors for developing ONJ (18). However, 
patients with hip fractures may present with anemia due to 
bleeding, making it difficult to grasp as an inherent risk factor 
for ONJ. The presence of malignant tumors may exacerbate the 
oral environment (21). However, it is often associated with other 
general conditions of the patient. In this study, there was no sig-
nificant difference in the necessity of dental intervention among 
malignant tumor patients with hip fractures, and it was not an 
inherent risk. Thus, because various factors are involved in the 
oral condition, our method of judging from the number of risk 
factors was considered to be exceedingly meaningful.
It is challenging to pay multiple visits to the dentist after 
undergoing an operation for a hip fracture. Thus, it may not 
be possible to encourage all patients to visit a dental office. For 
this reason, it may be useful to recommend a dental visit to a 
patient with a high-risk factor of ≥ 2 with the cooperation of a 
family member or to request a visiting dentist. This is an im-
portant factor for orthopedists and co-medical staff in managing 
patients following discharge. It has been reported that patients 
who receive regular oral maintenance by dentists and those who 
maintain their oral environment were at low risk of developing 
ONJ, even if the dose of antiresorptive agents was increased (18). 
The Cochrane Systematic Review reported that the risk ratio 
was 0.10 (95% confidence interval 0.02-0.39) for the occurrence 
of ONJ every three months for oral care compared with standard 
care (22). This is also important from a long-term patient man-
agement perspective.
There are several limitations to this research. Firstly, an 
evaluation of the oral cavity for all surgically treated patients 
with hip fractures is not performed. Although it is conducted by a 
system that asks for a dentist, all patients could not be evaluated 
because of timing difficulties and obtaining consent from the 
medical staff. Secondly, the number of risk factors was simply 
calculated without considering the weighting of the risk factors. 
If there were a larger number of cases, it would be possible to con-
duct a more accurate study by comprehensively analyzing with 
a predictive score that considered the weighting of risk factors. 
It is hoped that more cases will be accumulated and studied in 
the future.
CONCLUSION
For patients with hip fracture with more than 2 risk factors, 
dental visits are recommended to prevent ARONJ. This is a 
useful evaluation method that can be used to screen for ONJ 
from other risk factors, even if it is difficult to evaluate the oral 
condition in hospitals where dentists are absent. 
Table 3.　Number of risk factors for osteonecrosis of the jaw and sen-
sitivity specificity.
Sensitivity and specificity between the number of risk factors for os-
teonecrosis of the jaw and oral condition requiring dental intervention
Number of risk factor Sensitivity (%) Specificity (%)
1 or more 100 14.1
2 or more 87.5 53.5
3 or more 50.0 78.9
4 or more 25.0 90.1
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